Portfolio and franchise teams that rank assets, allocate investment across therapy areas and decide where the company should build depth.
Early commercial input into pipeline assets: market assessment, target product profiles, label testing and the commercial case for development.
Choosing the indications, patient populations and trial design inputs that give an asset the best chance of clinical and commercial success.
Extending and protecting value through new indications, formulations, combinations and loss-of-exclusivity planning.
Risk-adjusted valuation, scenario modelling and forecasts that underpin portfolio, deal and investment decisions.
Consultancies advising pharma, biotech and investors on prioritisation, asset strategy and pipeline value.